ArticleTranslational vision science & technology2025
Comparison of Methods for Visual Field Progression in Eyes With Central Visual Field Defects.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward Long-Term Visual Field Appearance Forecasting Using Artificial Intelligence for Ophthalmic Education and Diagnosis.Ophthalmology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: To investigate the agreement of various criteria for visual field (VF) progression in eyes with central VF defects, and to evaluate their performance in simulation datasets with and without age-related and glaucomatous change. Methods: A total of 282 eyes of 197 primary open-angle glaucoma patients with 10-2 central VF defect at baseline with two or more years' follow-up and five or more visits for both 10-2 and 24-2 VF were included. Various progression detection methods were used: 10-2 clustered pointwise linear regression (PLR), 10-2 VF mean deviation (MD), 24-2 central VF mean total deviation (MTD), 24-2 VF MD, 24-2 PLR, guided progression analysis, Advanced Glaucoma Intervention Study, and Collaborative Initial Glaucoma Treatment Study scores. Progression was defined as a binary outcome at the final visit: ≤-0.7 dB/year for 10-2 VF MD and ≤-0.5 or ≤-1.0 dB/year for 24-2 central VF MTD. Pairwise agreements were evaluated using Cohen's kappa. To further assess the detection performance under controlled conditions, two simulation datasets were constructed: one incorporating realistic progression and another with no true change. The t-statistics from ordinary least squares regression were used to compute receiver operating characteristic curves and normalized partial area under the curves. Results: Central progression was more frequently detected with 10-2 VF: 10-2 VF MD (35.1%) and 10-2 clustered PLR (20.6%) versus 24-2 central VF MTD at ≤-0.5 dB/y (17.7%) and ≤-1.0 dB/y (3.2%). Global progression was observed in 17.7% to 30.5%. The agreement among methods ranged from 67.0% to 85.1%, with kappas values of 0.11-0.25 between 10-2 and 24-2 MTD methods and 0.22-0.54 between 10-2 and 24-2 methods. Simulation analyses confirmed that 10-2 VF MD had the highest partial AUC across specificity levels. Conclusions: Agreement among methods for central VF progression monitoring is low to moderate. Concordance between 24-2 and 10-2 VF methods is variable, with 10-2 detecting a higher proportion of central progression. Translational Relevance: Incorporating 10-2 VF testing alongside 24-2 is essential, as relying solely on 24-2 VF may underestimate central VF progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.